Cited by 333Cancer Mechanisms and TherapyComputational Drug Discovery MethodsMetabolism, Diabetes, and Cancer

The DOI matches its Crossref record; 326 of the 333 references it cites were found in a registry or an index.

Drug repurposing in cancer

Sleire, Linda, Førde, Hilde Elise, Netland, Inger Anne, Leiss, Lina, Skeie, Bente Sandvei, Enger, Per Øyvind·2017·Pharmacological Research

DOI 10.1016/j.phrs.2017.07.013

Open this paper in CoChat — free account

Abstract

Cancer is a major health issue worldwide, and the global burden of cancer is expected to increase in the coming years. Whereas the limited success with current therapies has driven huge investments into drug development, the average number of FDA approvals per year has declined since the 1990s. This unmet need for more effective anti-cancer drugs has sparked a growing interest for drug repurposing, i.e. using drugs already approved for other indications to treat cancer. As such, data both from pre-clinical experiments, clinical trials and observational studies have demonstrated anti-tumor efficacy for compounds within a wide range of drug classes other than cancer. Whereas some of them induce cancer cell death or suppress various aspects of cancer cell behavior in established tumors, others may prevent cancer development. Here, we provide an overview of promising candidates for drug repurposing in cancer, as well as studies describing the biological mechanisms underlying their anti-neoplastic effects.

Integrity signals

Registry

Crossref · 10.1016/j.phrs.2017.07.013

Cites

326 of 326 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
The TNF and TNF Receptor Superfamilies
Locksley, R. M., Killeen, N., & Lenardo, M. J. (2001) · Cell · doi:10.1016/s0092-8674(01)00237-9 · Cited by 3,650
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene<SUBTITLE>Results From a 3-Year Randomized Clinical Trial</SUBTITLE>
Ettinger, B. (1999) · JAMA · doi:10.1001/jama.282.7.637 · Cited by 3,366
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
A molecular mechanism for the effect of lithium on development.
Klein, P. S., & Melton, D. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8455 · Cited by 2,334
World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015
McGuire, S. (2016) · Advances in Nutrition · doi:10.3945/an.116.012211 · Cited by 1,900
The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial
Cummings, S. R., Eckert, S., Krueger, K. A., Grady, D., Powles, T. J., Cauley, J. A., Norton, L., Nickelsen, T., Bjarnason, N. H., Morrow, M., et al. (1999) · JAMA · doi:10.1001/jama.281.23.2189 · Cited by 1,872
Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes<SUBTITLE>The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial</SUBTITLE>
Vogel, V. G. (2006) · JAMA · doi:10.1001/jama.295.23.joc60074 · Cited by 1,652

Show all 333 references

Sorted by citations

The updated landscape of tumor microenvironment and drug repurposing
Jin, M.-Z., & Jin, W.-L. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00280-x · Cited by 1,262
Overcoming cancer therapeutic bottleneck by drug repurposing
Zhang, Z., Zhou, L., Xie, N., Nice, E. C., Zhang, T., Cui, Y., & Huang, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00213-8 · Cited by 544
Old Drugs as New Treatments for Neurodegenerative Diseases
Durães, F., Pinto, M. M. M., & Sousa, E. (2018) · Pharmaceuticals · doi:10.3390/ph11020044 · Cited by 362
Polytherapy and Targeted Cancer Drug Resistance
Chatterjee, N., & Bivona, T. G. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.02.003 · Cited by 277
Disulfiram Copper Nanoparticles Prepared with a Stabilized Metal Ion Ligand Complex Method for Treating Drug-Resistant Prostate Cancers
Chen, W., Yang, W. L., Chen, P., Huang, Y., & Li, F. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b14940 · Cited by 155
Current status and contemporary approaches to the discovery of antitumor agents from higher plants
Agarwal, G., Carcache, P. J. B., Addo, E. M., & Kinghorn, A. D. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.01.004 · Cited by 116
Coordinate β-adrenergic inhibition of mitochondrial activity and angiogenesis arrest tumor growth
Nuevo‐Tapioles, C., Santacatterina, F., Stamatakis, K., de Arenas, C. N., de Cedrón, M. G., Formentini, L., & Cuezva, J. M. (2020) · Nature Communications · doi:10.1038/s41467-020-17384-1 · Cited by 117
Drug combination and repurposing for cancer therapy: the example of breast cancer
Correia, A. S., Gärtner, F., & Vale, N. (2021) · Heliyon · doi:10.1016/j.heliyon.2021.e05948 · Cited by 113
Drug repurposing to fight colistin and carbapenem-resistant bacteria
Peyclit, L., Baron, S. A., & Rolain, J.-M. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00193 · Cited by 91
New drugs are not enough‑drug repositioning in oncology: An update
Armando, R., Mengual G�mez, D., & Gomez, D. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.4966 · Cited by 90
Repurposing of plant alkaloids for cancer therapy: Pharmacology and toxicology
Efferth, T., & Oesch, F. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.010 · Cited by 91
Old wine in new bottles: Drug repurposing in oncology
Antoszczak, M., Markowska, A., Markowska, J., & Huczyński, A. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172784 · Cited by 91
Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway
Wang, X., Wu, X., Zhang, Z., Ma, C., Wu, T., Tang, S., Zeng, Z., Huang, S., Gong, C., Yuan, C., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-36214-5 · Cited by 85
Improving therapy of severe infections through drug repurposing of synergistic combinations
Cheng, Y., Williamson, P. R., & Zheng, W. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.07.006 · Cited by 84
Repurposing non-oncology small-molecule drugs to improve cancer therapy: Current situation and future directions
Fu, L., Jin, W., Zhang, J., Zhu, L., Lu, J., Zhen, Y., Zhang, L., Ouyang, L., Liu, B., & Yu, H. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.09.006 · Cited by 83
Development of inhalable quinacrine loaded bovine serum albumin modified cationic nanoparticles: Repurposing quinacrine for lung cancer therapeutics
Vaidya, B., Kulkarni, N. S., Shukla, S. K., Parvathaneni, V., Chauhan, G., Damon, J. K., Sarode, A., Garcia, J., Kunda, N. K., Mitragotri, S., et al. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118995 · Cited by 80
Understanding Membrane Protein Drug Targets in Computational Perspective
Gong, J., Chen, Y., Pu, F., Sun, P., He, F., Zhang, L., Li, Y., Ma, Z., & Wang, H. (2018) · Current Drug Targets · doi:10.2174/1389450120666181204164721 · Cited by 82
Repurposing approved non-oncology drugs for cancer therapy: a comprehensive review of mechanisms, efficacy, and clinical prospects
Mohi-ud-din, R., Chawla, A., Sharma, P., Mir, P. A., Pottoo, F. H., Reiner, Ž., Reiner, I., Ateşşahin, D. A., Sharifi‐Rad, J., Mir, R. H., et al. (2023) · European journal of medical research · doi:10.1186/s40001-023-01275-4 · Cited by 84
Recent contributions of quinolines to antimalarial and anticancer drug discovery research
de Walle, T. V., Cools, L., Mangelinckx, S., & D’hooghe, M. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113865 · Cited by 80
Inhalation delivery of repurposed drugs for lung cancer: Approaches, benefits and challenges
Kumbhar, P., Manjappa, A. S., Shah, R., Jha, N. K., Singh, S. K., Dua, K., Disouza, J., & Patravale, V. B. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.11.015 · Cited by 76
Metformin: prevention of genomic instability and cancer: a review
Najafi, M., Cheki, M., Rezapoor, S., Geraily, G., Motevaseli, E., Carnovale, C., Clementi, E., & Shirazi, A. (2018) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2018.01.007 · Cited by 75
SPHK1 Is a Novel Target of Metformin in Ovarian Cancer
Hart, P. C., Chiyoda, T., Liu, X., Weigert, M., Curtis, M., Chiang, C.-Y., Loth, R. M., Lastra, R. R., McGregor, S. M., Locasale, J. W., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0409 · Cited by 76
Knowledge-driven drug repurposing using a comprehensive drug knowledge graph
Zhu, Y., Che, C., Jin, B., Zhang, N., Su, C., & Wang, F. (2020) · Health Informatics Journal · doi:10.1177/1460458220937101 · Cited by 73
Drug repurposing for viral cancers: A paradigm of machine learning, deep learning, and virtual screening‐based approaches
Ahmed, F., Kang, I. S., Kim, K. H., Asif, A., Rahim, C. S. A., Samantasinghar, A., Memon, F. H., & Choi, K. H. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28693 · Cited by 75
Drug repurposing and relabeling for cancer therapy: Emerging benzimidazole antihelminthics with potent anticancer effects
Nath, J., Paul, R., Ghosh, S. K., Paul, J., Singha, B., & Debnath, N. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118189 · Cited by 71
Statin as a Potential Chemotherapeutic Agent: Current Updates as a Monotherapy, Combination Therapy, and Treatment for Anti-Cancer Drug Resistance
Pun, N. T., & Jeong, C. (2021) · Pharmaceuticals · doi:10.3390/ph14050470 · Cited by 75
Oroxylin A: A Promising Flavonoid for Prevention and Treatment of Chronic Diseases
Sajeev, A., Hegde, M., Girisa, S., Devanarayanan, T. N., Alqahtani, M. S., Abbas, M. A. E., Sil, S. K., Sethi, G., Chen, J., & Kunnumakkara, A. B. (2022) · Biomolecules · doi:10.3390/biom12091185 · Cited by 69
Metronomic chemotherapy and drug repurposing: A paradigm shift in oncology
Jan, N., Sofi, S., Qayoom, H., Shabir, A., Haq, B. U., Macha, M. A., Almilaibary, A., & Mir, M. A. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24670 · Cited by 68
Drug Repurposing in Cancer Therapy: Influence of Patient’s Genetic Background in Breast Cancer Treatment
Rodrigues, R. C., Duarte, D., & Vale, N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084280 · Cited by 68
Anthelmintics for drug repurposing: Opportunities and challenges
Alavi, S. E., & Shahmabadi, H. E. (2021) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2021.04.004 · Cited by 66
Repurposing drugs for glioblastoma: From bench to bedside
Basso, J., Miranda, A., Sousa, J., Pais, A. A. C. C., & Vitorino, C. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.04.039 · Cited by 63
New Approaches in Oncology for Repositioning Drugs: The Case of PDE5 Inhibitor Sildenafil
Cruz-Burgos, M., Losada-García, A., Cruz-Hernández, C. D., Cortés-Ramírez, S. A., Camacho‐Arroyo, I., González-Covarrubias, V., Morales-Pacheco, M., Trujillo-Bornios, S. I., & Rodríguez‐Dorantes, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.627229 · Cited by 63
Glutathione-responsive copper-disulfiram nanoparticles for enhanced tumor chemotherapy
Chen, M., Huang, Z., Xia, M., Ding, Y., Shan, T., Guan, Z., Dai, X., Xu, X., Huang, Y., Huang, M., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.11.041 · Cited by 62
Repurposing Artemisinin and its Derivatives as Anticancer Drugs: A Chance or Challenge?
Ma, Z., Woon, C. Y.-N., Liu, C., Cheng, J.-T., You, M., Sethi, G., Wong, A. L., Ho, P. C., Zhang, D., Ong, P.-S., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.828856 · Cited by 63
Biomimetic metal-organic nanoparticles prepared with a 3D-printed microfluidic device as a novel formulation for disulfiram-based therapy against breast cancer
Chang, Y., Jiang, J., Wu, C., Yang, W. L., Chen, L., Chen, P., Shen, J., Qian, S., Zhou, T., Wu, L., et al. (2019) · Applied Materials Today · doi:10.1016/j.apmt.2019.100492 · Cited by 63
Drug rechanneling: A novel paradigm for cancer treatment
Kaushik, I., Ramachandran, S., Prasad, S., & Srivastava, S. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.03.011 · Cited by 60
The antipsychotic chlorpromazine suppresses YAP signaling, stemness properties, and drug resistance in breast cancer cells
Yang, C.-E., Lee, W., Cheng, H., Chung, C., Mi, F.-L., & Lin, C. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.01.033 · Cited by 57
Repurposing Itraconazole Loaded PLGA Nanoparticles for Improved Antitumor Efficacy in Non-Small Cell Lung Cancers
Alhakamy, N. A., & Md, S. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11120685 · Cited by 57
Dual inhibition of thioredoxin reductase and proteasome is required for auranofin-induced paraptosis in breast cancer cells
Seo, M. J., Kim, I. Y., Lee, D. M., Park, Y. J., Cho, M. Y., Jin, H. J., & Choi, K. S. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05586-6 · Cited by 56
Drug Repurposing for Cancer Treatment: A Comprehensive Review
Khzem, A. H. A., Gomaa, M. S., Alturki, M. S., Tawfeeq, N., Sarafroz, M., Alonaizi, S. M., Faran, A. A., Alrumaihi, L. A., AlAnsari, F., & Alghamdi, A. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212441 · Cited by 61
Pathway-Based Drug-Repurposing Schemes in Cancer: The Role of Translational Bioinformatics
Lemus, E. H., & Martínez-García, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.605680 · Cited by 57
The Benzimidazole-Based Anthelmintic Parbendazole: A Repurposed Drug Candidate That Synergizes with Gemcitabine in Pancreatic Cancer
Florio, R., Veschi, S., di Giacomo, V., Pagotto, S., Carradori, S., Verginelli, F., Cirilli, R., Casulli, A., Grassadonia, A., Tinari, N., et al. (2019) · Cancers · doi:10.3390/cancers11122042 · Cited by 54
Diuretics: a contemporary pharmacological classification?
Kehrenberg, M. C. A., & Bachmann, H. S. (2022) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-022-02228-0 · Cited by 53
Drug repurposing—an emerging strategy in cancer therapeutics
Turabi, K. S., Deshmukh, A. J., Paul, S., Swami, D., Siddiqui, S., Kumar, U., Naikar, S., Devarajan, S., Basu, S., Paul, M. K., et al. (2022) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-022-02263-x · Cited by 53
Discovery of VEGFR2 inhibitors by integrating naïve Bayesian classification, molecular docking and drug screening approaches
Kang, D., Pang, X., Lian, W., Xu, L., Wang, J., Jia, H., Zhang, B., Liu, A., & Du, G. (2018) · RSC Advances · doi:10.1039/c7ra12259d · Cited by 53
Drug Repurposing - Hypothesis, Molecular Aspects and Therapeutic Applications
Badria, F. A.-E. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.83082 · Cited by 52
Repositioning of Anthelmintic Drugs for the Treatment of Cancers of the Digestive System
Laudisi, F., Marônek, M., Grazia, A. D., Monteleone, G., & Stolfi, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144957 · Cited by 57
Subterminal hydroxyeicosatetraenoic acids: Crucial lipid mediators in normal physiology and disease states
Shoieb, S. M., El-Sherbeni, A. A., & El‐Kadi, A. O. S. (2018) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2018.12.004 · Cited by 50
Molecular mechanisms of anti-psychotic drugs for improvement of cancer treatment
Hendouei, N., Saghafi, F., Shadfar, F., & Hosseinimehr, S. J. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.05.031 · Cited by 49
Histone Demethylase KDM5B as a Therapeutic Target for Cancer Therapy
Jose, A., Shenoy, G. G., Rodrigues, G. S., Kumar, N. A. N., Munisamy, M., Thomas, L., Kolesar, J., Rai, G., Rao, P. P. N., & Rao, M. (2020) · Cancers · doi:10.3390/cancers12082121 · Cited by 49
Psychotropic Drugs Show Anticancer Activity by Disrupting Mitochondrial and Lysosomal Function
Varalda, M., Antona, A., Bettio, V., Roy, K., Vachamaram, A., Yellenki, V., Massarotti, A., Baldanzi, G., & Capello, D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.562196 · Cited by 50
Ligand and Structure-Based In Silico Determination of the Most Promising SARS-CoV-2 nsp16-nsp10 2′-o-Methyltransferase Complex Inhibitors among 3009 FDA Approved Drugs
Eissa, I. H., Alesawy, M. S., Saleh, A. M., Elkaeed, E. B., Alsfouk, B. A. A., El-Attar, A.-A. M. M., & Metwaly, A. M. (2022) · Molecules · doi:10.3390/molecules27072287 · Cited by 49
Statins as anti‐tumor agents: A paradigm for repurposed drugs
Tripathi, S., Gupta, E., & Galande, S. (2024) · Cancer Reports · doi:10.1002/cnr2.2078 · Cited by 52
The Allergic Rhinitis and Its Impact on Asthma (ARIA) Approach of Value-Added Medicines: As-Needed Treatment in Allergic Rhinitis
Bousquet, J., Toumi, M., Sousa‐Pinto, B., Antó, J. M., Bedbrook, A., Czarlewski, W., Valiulis, A., Ansotegui, I. J., Bosnic-Anticevich, S. Z., Brussino, L., et al. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2022.07.020 · Cited by 56
New perspectives in cancer: Modulation of lipid metabolism and inflammation resolution
Prevete, N., Liotti, F., Amoresano, A., Pucci, P., de Paulis, A., & Melillo, R. M. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.09.024 · Cited by 48
Somatic selection distinguishes oncogenes and tumor suppressor genes
Chandrashekar, P. B., Ahmadinejad, N., Wang, J., Sekulić, A., Egan, J. B., Asmann, Y. W., Kumar, S., Maley, C. C., & Liu, L. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz851 · Cited by 47
Targeting the Tumor Extracellular Matrix by the Natural Molecule 4-Methylumbelliferone: A Complementary and Alternative Cancer Therapeutic Strategy
Vitale, D. L., Icardi, A., Rosales, P., Spinelli, F. M., Sevic, I., & Alaniz, L. D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.710061 · Cited by 48
Drug repurposing: re-inventing therapies for cancer without re-entering the development pipeline—a review
Siddiqui, S., Deshmukh, A. J., Mudaliar, P., Nalawade, A. J., Iyer, D., & Aich, J. (2022) · Journal of the Egyptian National Cancer Institute · doi:10.1186/s43046-022-00137-0 · Cited by 44
Inhibition of Chloride Intracellular Channel 1 (CLIC1) as Biguanide Class-Effect to Impair Human Glioblastoma Stem Cell Viability
Barbieri, F., Würth, R., Pattarozzi, A., Verduci, I., Mazzola, C., Cattaneo, M. G., Tonelli, M., Solari, A., Bajetto, A., Daga, A., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00899 · Cited by 46
A unified platform enabling biomarker ranking and validation for 1562 drugs using transcriptomic data of 1250 cancer cell lines
Fekete, J. T., & Győrffy, B. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.06.007 · Cited by 43
Beta-adrenergic receptor blocker propranolol triggers anti-tumor immunity and enhances irinotecan therapy in mice colorectal cancer
Lin, Y., Liu, Y., Gao, Z., Jing, D., Bi, R., Cui, X., Cao, Q., Zhao, Q., Gao, R., Su, Y., et al. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175718 · Cited by 43
Timosaponin AIII: A novel potential anti-tumor compound from Anemarrhena asphodeloides
Feng-ying, H., Song, X., Chen, J., Yao, G., & Song, S. (2018) · Steroids · doi:10.1016/j.steroids.2018.09.014 · Cited by 43
Repurposing of Chronically Used Drugs in Cancer Therapy: A Chance to Grasp
Hijazi, M. A., Gessner, A., & El‐Najjar, N. (2023) · Cancers · doi:10.3390/cancers15123199 · Cited by 44
Mesothelial Cell HIF1α Expression Is Metabolically Downregulated by Metformin to Prevent Oncogenic Tumor-Stromal Crosstalk
Hart, P. C., Kenny, H. A., Graßl, N., Watters, K. M., Litchfield, L. M., Coscia, F., Blaženović, I., Ploetzky, L., Fiehn, O., Mann, M., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.11.079 · Cited by 41
Metformin suppresses HIF‐1α expression in cancer‐associated fibroblasts to prevent tumor‐stromal cross talk in breast cancer
Shao, S., Zhao, L., An, G., Zhang, L., Jing, X., Luo, M., Li, W., Du, M., Ning, Q., Zhao, X., et al. (2020) · The FASEB Journal · doi:10.1096/fj.202000951rr · Cited by 42
Current Treatments and New Possible Complementary Therapies for Epithelial Ovarian Cancer
Garrido, M. P., Fredes, A. N., Lobos‐González, L., Valenzuela, M., Vera, D. B., & Romero, C. (2021) · Biomedicines · doi:10.3390/biomedicines10010077 · Cited by 42
Integration of genetic variants and gene network for drug repurposing in colorectal cancer
Irham, L. M., Wong, H. S.-C., Chou, W., Adikusuma, W., Mugiyanto, E., Huang, W., & Chang, W. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105203 · Cited by 44
Exploring the SARS-CoV-2 Proteome in the Search of Potential Inhibitors via Structure-Based Pharmacophore Modeling/Docking Approach
Culletta, G., Gulotta, M. R., Perricone, U., Zappalà, M., Almerico, A. M., & Tutone, M. (2020) · Computation · doi:10.3390/computation8030077 · Cited by 40
Drug Repurposing for the Treatment of Acute Myeloid Leukemia
Andresen, V., & Gjertsen, B. T. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00211 · Cited by 40
Artificial Intelligence in Drug Discovery and Development Against Antimicrobial Resistance: A Narrative Review
Ghaderzadeh, M., Shalchian, A., Irajian, G., Sadeghsalehi, H., Bialvaei, A. Z., & Sabet, B. (2024) · Iranian Journal of Medical Microbiology · doi:10.30699/ijmm.18.3.135 · Cited by 38
Dual Effect of Doxazosin: Anticancer Activity on SH-SY5Y Neuroblastoma Cells and Neuroprotection on an In Vitro Model of Alzheimer's Disease
Coelho, B. P., Gaelzer, M. M., Petry, F. D. S., Hoppe, J. B., Trindade, V. M. T., Salbego, C. G., & Guma, F. T. C. R. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.02.005 · Cited by 38
DLDTI: a learning-based framework for drug-target interaction identification using neural networks and network representation
Zhao, Y., Zheng, K., Guan, B., Guo, M., Song, L., Gao, J., Qu, H., Wang, Y., Zhang, Y., & Dazhuo, S. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02602-7 · Cited by 38
Strategy of targeting the tumor microenvironment via inhibition of fibroblast/fibrosis remodeling new era to cancer chemo-immunotherapy resistance
Tajaldini, M., Poorkhani, A., Amiriani, T., Amiriani, A., Javid, H., Aref, P., Ahmadi, F., Sadani, S., & Khori, V. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175991 · Cited by 38
Connectivity map-based drug repositioning of bortezomib to reverse the metastatic effect of GALNT14 in lung cancer
Kwon, O., Lee, H., Kong, H., Kwon, E.-J., Park, J. E., Lee, W., Kang, S., Kim, S., Kim, W., & Cha, H. (2020) · Oncogene · doi:10.1038/s41388-020-1316-2 · Cited by 37
Discovery of novel BET inhibitors by drug repurposing of nitroxoline and its analogues
Jiang, H., Xing, J., Wang, C., Zhang, H., Yue, L., Wan, X., Chen, W., Ding, H., Xie, Y., Tao, H., et al. (2017) · Organic & Biomolecular Chemistry · doi:10.1039/c7ob02369c · Cited by 36
Synthesis and Characterization of Lipophilic Salts of Metformin to Improve Its Repurposing for Cancer Therapy
Saeed, H. K., Sutar, Y. B., Patel, P. A., Bhat, R., Mallick, S., Hatada, A. E., Koomoa, D. T., Lange, I., & Date, A. A. (2021) · ACS Omega · doi:10.1021/acsomega.0c04779 · Cited by 36
Repurposing some of the Well-known Non-steroid Anti-inflammatory Drugs (NSAIDs) for Cancer Treatment
Vasconcelos, M. H., Palmeira, A., Sousa, S. M., & Xavier, C. P. R. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666230130150029 · Cited by 36
Quinacrine-Induced Autophagy in Ovarian Cancer Triggers Cathepsin-L Mediated Lysosomal/Mitochondrial Membrane Permeabilization and Cell Death
Thirusangu, P., Pathoulas, C. L., Ray, U., Xiao, Y., Staub, J. K., Jin, L., Khurana, A., & Shridhar, V. (2021) · Cancers · doi:10.3390/cancers13092004 · Cited by 35
Self‐Degradable Nanogels Reshape Immunosuppressive Tumor Microenvironment via Drug Repurposing Strategy to Reactivate Cytotoxic CD8+ T Cells
Tian, H., Li, W., Wang, G., Tian, Y., Yan, J., Zhou, S., Yu, X., Li, B., & Dai, Y. (2023) · Advanced Science · doi:10.1002/advs.202301661 · Cited by 34
Phosphorylated STAT3 (Tyr705) as a biomarker of response to pimozide treatment in triple-negative breast cancer
Dees, S., Pontiggia, L., Jasmin, J.-F., & Mercier, I. (2020) · Cancer Biology & Therapy · doi:10.1080/15384047.2020.1726718 · Cited by 34
How selective are clinical CDK4/6 inhibitors?
Hendrychová, D., Jorda, R., & Kryštof, V. (2020) · Medicinal Research Reviews · doi:10.1002/med.21769 · Cited by 36
Verteporfin selectively kills hypoxic glioma cells through iron-binding and increased production of reactive oxygen species
Eales, K. L., Wilkinson, E. A., Cruickshank, G. S., Tucker, J. H. R., & Tennant, D. A. (2018) · Scientific Reports · doi:10.1038/s41598-018-32727-1 · Cited by 32
Repurposing of Acriflavine to Target Chronic Myeloid Leukemia Treatment
Nehme, R., Hallal, R., Dor, M. E., Kobeissy, F. H., Gouilleux, F., Mazurier, F., & Zibara, K. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200908114411 · Cited by 35
Combination of Disulfiram and Copper–Cysteamine Nanoparticles for an Enhanced Antitumor Effect on Esophageal Cancer
Chang, Y., Wu, F., Pandey, N. K., Chudal, L., Xing, M., Zhang, X., Nguyen, L., Liu, X., Liu, J. P., Chen, W., et al. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c00949 · Cited by 32
Propranolol inhibits neonatal Nav1.5 activity and invasiveness of MDA‐MB‐231 breast cancer cells: Effects of combination with ranolazine
Lee, A. E., Fraser, S. P., & Djamgoz, M. B. A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28868 · Cited by 32
Drug repositioning for cancer in the era of AI, big omics, and real-world data
Wieder, R., & Adam, N. R. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103730 · Cited by 39
AMPK activation induced by promethazine increases NOXA expression and Beclin-1 phosphorylation and drives autophagy-associated apoptosis in chronic myeloid leukemia
Medeiros, H. C. D., Colturato-Kido, C., Ferraz, L. S., Costa, C. A., Moraes, V., Paredes‐Gamero, E. J., Tersariol, I. L. S., & Rodrigues, T. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.108888 · Cited by 30
Screening of drug databank against WT and mutant main protease of SARS-CoV-2: Towards finding potential compound for repurposing against COVID-19
Sharma, T., Abohashrh, M., Baig, M. H., Dong, J.-J., Alam, M. M., Ahmad, I., & Irfan, S. (2021) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2021.02.059 · Cited by 30
Zafirlukast inhibits the growth of lung adenocarcinoma via inhibiting TMEM16A channel activity
Shi, S., Ma, B., Sun, F., Qu, C. F., Li, G., Shi, D., Liu, W., Zhang, H., & An, H. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101731 · Cited by 30
Systems Biology Understanding of the Effects of Lithium on Cancer
Ge, W., & Jakobsson, E. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00296 · Cited by 29
Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: A Mendelian randomization study
Gormley, M., Yarmolinsky, J., Dudding, T., Burrows, K., Martin, R. M., Thomas, S. J., Tyrrell, J., Brennan, P., Pring, M., Boccia, S., et al. (2021) · PLoS Genetics · doi:10.1371/journal.pgen.1009525 · Cited by 32
Identification of Novel Cdc7 Kinase Inhibitors as Anti-Cancer Agents that Target the Interaction with Dbf4 by the Fragment Complementation and Drug Repositioning Approach
Cheng, A. N., Lo, Y.-K., Lin, Y., Tang, T.-K., Hsu, C., Hsu, J. T.-A., & Lee, A. Y. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.09.030 · Cited by 29
Repositioning Aspirin to Treat Lung and Breast Cancers and Overcome Acquired Resistance to Targeted Therapy
Li, L., Hu, M., Wang, T., Chen, H., & Xu, L. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01503 · Cited by 28
Combining repurposed drugs to treat colorectal cancer
Duarte, D., & Vale, N. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.09.012 · Cited by 29
Drug repurposing: An emerging strategy in alleviating skin cancer
Kumbhar, P., Kole, K., Yadav, T., Bhavar, A., Waghmare, P., Bhokare, R., Manjappa, A., Jha, N. K., Chellappan, D. K., Shinde, S., et al. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175031 · Cited by 28
Drug Repurposing in Oncology: A Systematic Review of Randomized Controlled Clinical Trials
Ioakeim‐Skoufa, I., Tobajas-Ramos, N., Menditto, E., Aza‐Pascual‐Salcedo, M., Miguel, A. G., Orlando, V., González‐Rubio, F., Fanlo, A., AZA, C. L., Ostasz, E., et al. (2023) · Cancers · doi:10.3390/cancers15112972 · Cited by 31
Drug repurposing against Parkinson's disease by text mining the scientific literature
Zhu, Y., Jung, W., Wang, F., & Che, C. (2020) · Library Hi Tech · doi:10.1108/lht-08-2019-0170 · Cited by 29
Drug Repurposing Opportunities in Pancreatic Ductal Adenocarcinoma
Rebelo, R., Polónia, B. R. G., Santos, L. L., Vasconcelos, M. H., & Xavier, C. P. R. (2021) · Pharmaceuticals · doi:10.3390/ph14030280 · Cited by 30
Fusion genes as biomarkers in pediatric cancers: A review of the current state and applicability in diagnostics and personalized therapy
Vellichirammal, N. N., Chaturvedi, N. K., Joshi, S. S., Coulter, D. W., & Guda, C. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.11.015 · Cited by 25
Docusate-Based Ionic Liquids of Anthelmintic Benzimidazoles Show Improved Pharmaceutical Processability, Lipid Solubility, and in Vitro Activity against Cryptococcus neoformans
Sutar, Y. B., Fulton, S. R., Paul, S. K., Altamirano, S., Mhatre, S., Saeed, H. K., Patel, P. A., Mallick, S., Bhat, R., Patravale, V. B., et al. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00063 · Cited by 26

Authors: Sleire, L., Førde, H. E., Netland, I. A., Leiss, L., Skeie, B. S., & Enger, P. Ø.
Affiliations: University of Bergen (NO)
Haukeland University Hospital (NO)
Corresponding author: Enger, Per Øyvind
ORCID: Leiss, Lina
Skeie, Bente Sandvei
Venue: Pharmacological Research
Publisher: Elsevier BV
Published: 2017-10
Volume: 124
Pages: 74-91
ISSN: 1043-6618 (ISSN-L)
DOI: 10.1016/j.phrs.2017.07.013
OpenAlex: W2734327577
Cited by: 329
References: 333
Citations by year: 2026: 18 · 2025: 21 · 2024: 54 · 2023: 43 · 2022: 45 · 2021: 45 · 2020: 56 · 2019: 24 · 2018: 20 · 2017: 3
FWCI: 4.63
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Pharmacological Research (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Keywords: drug repurposing, cancer, anticancer agents, FDA-approved drugs, anticancer mechanism, cancer prevention, unmet medical needs, anticancer drug development
MeSH terms: Animals, Antineoplastic Agents, Humans, Neoplasms, Drug Repositioning

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Drug repurposing in cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks